Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Canerpaturev - Takara Bio

Drug Profile

Canerpaturev - Takara Bio

Alternative Names: C-REV; HF-10; Msc-2; TBI-1401

Latest Information Update: 05 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ms Science; Nagoya University
  • Developer Takara Bio; University of Utah
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Malignant melanoma
  • Phase I Pancreatic cancer
  • No development reported Head and neck cancer; Solid tumours

Most Recent Events

  • 01 Jun 2019 Efficacy results from the phase I trial in Soild tumours were presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 01 Jun 2019 Positive efficacy data from a phase II trial in Malignant melanoma presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 29 Mar 2019 Preregistration for Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (Intratumoural) (Otsuka Pharmaceuticals pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top